Bioinformatics firm Ariadne Genomics, Inc., US, has announced the launch of ChemEffect, a new Pathway Studio knowledge base that contains more than 425,000 biological facts and relationships linked to more than 17,000 small molecules, chemicals, and drugs.
ChemEffect can be customised and installed to work seamlessly within existing pharmaceutical infrastructure. Scientists in target validation and lead optimisation can rapidly characterise their drug targets and development leads against known effects or standards, often obtaining information that supports mechanistic hypotheses of drug action and toxicity.
Together, ChemEffect and Pathway Studio serve as a one-of-a-kind knowledge hub housing and integrating biological facts from public sources. Through this centralised hub, disparate types of data from public and proprietary sources can be linked and displayed through interactive, interpretive visual networks. Scientists can use in-house experimental data to build hypothetical associations between a compound and potential phenotypical outcomes such as drug action, side effects, and drug-drug interactions. By coupling these investigative tools, a more comprehensive information set can often be assembled to help guide and support development activities on lead compounds.
Pathway Studio draws on the power of MedScan, Ariadne's patent-pending technology for text mining, which provides an accurate and rapid means of keeping abreast of up-to-the-minute published findings and aids in critical drug development decision making. Proprietary algorithms help interpret experimental data: perform functional analysis, identify regulated pathways, or discover new biological networks.
